A0A2K6A443 (A0A2K6A443_MANLE) Mandrillus leucophaeus (Drill) (Papio leucophaeus)
Tyrosine-protein kinase UniProtKBInterProSTRINGInteractive Modelling
659 aa; Sequence (Fasta) ;
10 identical sequences: Homo sapiens: Q06187; Pan troglodytes: A0A2I3RVY9; Pan paniscus: A0A2R9BPC2; Gorilla gorilla gorilla: G3SKC9; Macaca nemestrina: A0A2K6CUV5; Macaca mulatta: F6V0I6, A0A8J8YBS4; Macaca fascicularis: A0A2K5VDZ2; Nomascus leucogenys: G1R7I9; Rhinopithecus roxellana: A0A2K6PTH4
Available Structures
133 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihyd… |
Heteromer Q06187; | 100 | 4×N42; | |||
| Structure of cIAP1, BTK and BCCov |
Heteromer Q06187; Q13490; | 100.0 | 1×TOO; 1×ZN; | |||
| Ternary complex structure - BTK cIAP compound 15 |
Heteromer Q06187; Q13490; | 100.0 | 1×ZN; 1×TKY; | |||
| Ternary complex structure - BTK cIAP compound 17 |
Heteromer Q06187; Q13490; | 100 | 1×TL7; 1×ZN; | |||
| Crystal structure of human Btk SH2 domain bound to rF10 repebody |
Heteromer Q06187; | 100 | ||||
| PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT E41K IN COMPLEX WITH INS(1,3,4,5)P4 | homo-4-mer | 99.4 | 4×ZN; 8×4IP; | |||
| PH DOMAIN FROM BRUTON'S TYROSINE KINASE IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATE | homo-4-mer | 100.0 | 4×ZN; 4×4IP; | |||
| The Crystal Structure of BTK from Biortus | homo-2-mer | 100.0 | 1×PEG; 4×EDO; 2×CL; | |||
| The structure of human BTK kinase domain in complex with a covalent inhibitor | homo-2-mer | 100.0 | 2×GYL; | |||
| CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO … | homo-2-mer | 100.0 | 2×6MV; | |||
| Crystal structure of Bruton's tyrosine kinase domain | homo-2-mer | 100 | ||||
| PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT R28C | homo-2-mer | 99.38 | 2×ZN; 2×NA; | |||
| CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGAND | monomer | 100 | 1×GJD; | |||
| BTK1 SOAKED WITH IBRUTINIB-Rev | monomer | 100 | 1×1E8; 2×DMS; | |||
| CRYSTAL STRUCTURE OF BTK with CNX 774 | monomer | 100 | 1×7G8; | |||
| CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND | monomer | 100 | 1×GJG; | |||
| Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-… | monomer | 100 | 1×83P; 3×EDO; 2×PEG; | |||
| BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED | monomer | 100 | 1×X9M; | |||
| BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxy… | monomer | 100 | 1×KLM; 6×EDO; | |||
| Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinib | monomer | 100 | 1×CL; 1×MZJ; | |||
| BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059 | monomer | 100 | 1×7GB; 1×DMS; | |||
| CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR | monomer | 100 | 1×GJ7; 1×DMS; | |||
| Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R… | monomer | 100.0 | 1×4US; 1×DMS; 2×EDO; | |||
| Bruton's tyrosine kinase (BTK) with GDC-0853 | monomer | 100 | 1×9AJ; 8×EDO; 2×SO4; | |||
| Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinase | monomer | 100 | 2×IMD; 1×IPA; 1×EDO; 1×4L6; | |||
| BTK1 SOAKED WITH COMPOUND 25 | monomer | 100 | 1×X9V; 4×DMS; | |||
| BTK in complex with 18A | monomer | 100 | 1×2IE; | |||
| Discovery of affinity-based probes for Btk occupancy assay | monomer | 100 | 1×KHD; | |||
| Crystal structure of ARQ 531 in complex with the kinase domain of BTK | monomer | 100 | 1×HRA; 2×IMD; 2×EDO; | |||
| Crystal structure of the noncovalently bonded complex of rilzabrutinib with BTK | monomer | 100.0 | 1×R1L; 1×DMS; 1×PEG; 2×EDO; 1×SO4; 1×ACT; | |||
| Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor | monomer | 100 | 1×IMD; 1×PGO; 1×0BQ; 1×EDO; | |||
| BTK1 SOAKED WITH COMPOUND 30 | monomer | 100 | 2×DMS; 1×X9Y; | |||
| BTK in complex with 25A | monomer | 100.0 | 1×2IJ; 2×DMS; | |||
| Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor | monomer | 100 | 1×IMD; 1×EDO; 1×DMS; 1×0UW; | |||
| Bruton's tyrosine kinase in complex with 3-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-5-[(3R)-3-(3-m… | monomer | 100 | 1×WKC; 2×EDO; 1×PD; 1×CL; | |||
| Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor | monomer | 100.0 | 1×IMD; 1×PGO; 2×DMS; 1×0GW; | |||
| Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragment | monomer | 100 | 2×IMD; 1×IPA; 1×DMS; 1×4RU; | |||
| Fragment-Based Drug Design of a Novel, Covalent Bruton's Tyrosine Kinase Inhibitor | monomer | 100 | 1×IMD; 1×0CI; 1×DMS; | |||
| Bruton's tyrosine kinase in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyra… | monomer | 100 | 1×YXJ; 2×EDO; 1×CL; | |||
| Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[… | monomer | 100 | 1×UP9; 2×EDO; 1×CL; 1×IOD; | |||
| Bruton's tyrosine kinase (BTK) with compound 13 | monomer | 100 | 1×UB6; 1×PGE; | |||
| Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[… | monomer | 100 | 1×UQX; 1×NA; 1×CL; 2×SO4; 1×EDO; | |||
| Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnoline | monomer | 100 | 2×IMD; 1×IPA; 1×DMS; 1×4RV; | |||
| Crystal structure of BTK kinase domain complexed with 2-[4-(2-Diethylamino-ethoxy)-phenylamino]-6-(… | monomer | 100.0 | 1×04K; | |||
| Crystal structure of BTK kinase domain complexed with 2-Methyl-5-[(E)-(3-phenyl-acryloyl)amino]-N-(… | monomer | 100.0 | 1×04L; | |||
| Crystal structure of BTK kinase domain complexed with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-… | monomer | 100.0 | 2×LHL; | |||
| Crystal structure of BTK kinase domain complexed with (5-Amino-1-o-tolyl-1H-pyrazol-4-yl)-[3-(1-met… | monomer | 100.0 | 1×03C; | |||
| CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR | monomer | 100.0 | 1×GJJ; 1×DMS; | |||
| BTK In Complex With Inhibitor | monomer | 100.0 | 1×LTJ; | |||
| Crystal structure of BTK kinase domain complexed with 2-Isopropyl-7-(4-methyl-piperazin-1-yl)-4-(5-… | monomer | 100 | 1×027; | |||
| BTK-inhibitor co-structure | monomer | 100.0 | 1×5WH; 1×5WE; | |||
| Co-structure of BTK kinase domain with L-005085737 inhibitor | monomer | 100.0 | 1×ULV; 1×5WE; | |||
| Crystal structure of the covalently bonded complex of rilzabrutinib with BTK | monomer | 100 | 1×R1L; 2×SO4; | |||
| Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor | monomer | 100 | 1×4C9; 9×NA; 2×EDO; 2×SO4; 3×CL; | |||
| BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazo… | monomer | 100.0 | 1×KLP; 2×SO4; | |||
| Crystal structure of BTK kinase domain complexed with R406 | monomer | 100.0 | 1×585; | |||
| Co-crystal structure of BTK kinase domain with Zanubrutinib | monomer | 100 | 1×BA0; 1×IMD; | |||
| Bruton's tyrosine kinase in complex with compound 34 | monomer | 100 | 1×ZB9; 3×DMS; 1×PEG; | |||
| Bruton's tyrosine kinase in complex with compound 5 | monomer | 100.0 | 2×DMS; 1×RQS; | |||
| Bruton's tyrosine kinase in complex with compound 45 | monomer | 100.0 | 1×0B9; | |||
| Bruton's tyrosine kinase in complex with compound 6 | monomer | 100 | 1×DMS; 1×DTT; 1×S5M; | |||
| Bruton's tyrosine kinase in complex with an orthosteric inhibitor | monomer | 100.0 | 2×DMS; 1×Y8H; | |||
| The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-containi… | monomer | 100.0 | 1×B43; | |||
| Bruton's tyrosine kinase L528W mutant in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phen… | monomer | 99.61 | 1×YXJ; 5×EDO; | |||
| BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED | monomer | 100 | 1×X9J; 3×DMS; | |||
| Structures of human Bruton's tyrosine kinase in active and inactive conformations suggests a mechan… | monomer | 100.0 | 1×1N1; | |||
| CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND | monomer | 100.0 | 1×GJA; | |||
| BTK1 COCRYSTALLIZED WITH IBRUTINIB | monomer | 100.0 | 1×8E8; | |||
| BTK1 IN COMPLEX WITH CC 292 | monomer | 100.0 | 1×7G9; | |||
| Co-structure of BTK kinase domain with L-005298385 inhibitor | monomer | 100 | 2×UM4; 1×EDO; 1×BTB; | |||
| BTK1 SOAKED WITH COMPOUND 26 | monomer | 100 | 1×X9P; 2×DMS; | |||
| Bruton's tyrosine kinase in complex with compound 1 | monomer | 100.0 | 1×S9A; 1×DMS; | |||
| Bruton's tyrosine kinase in complex with covalent inhibitor compound 25 | monomer | 100.0 | 1×V72; | |||
| Bruton's tyrosine kinase in complex with compound 21 | monomer | 100.0 | 1×0BG; 1×DMS; | |||
| Bruton's tyrosine kinase in complex with compound 23 | monomer | 100.0 | 1×YD7; 1×DMS; | |||
| Bruton's tyrosine kinase in complex with covalent inhibitor compound 10 | monomer | 100.0 | 1×UEO; | |||
| BTK IN COMPLEX WITH GDC-0834 | monomer | 100 | 1×2VL; 4×EDO; 1×GOL; | |||
| BTK in complex with LOU064, a potent and highly selective covalent inhibitor | monomer | 100 | 1×NA; 1×N6Z; | |||
| BTK complex with compound 12 | monomer | 100 | 3×SO4; 1×DXM; 1×FPZ; 2×GOL; | |||
| Bruton's tyrosine kinase in complex with compound 51 | monomer | 100 | 1×YDA; 1×DTT; 2×ACT; | |||
| Brutons tyrosine kinase in complex with compound 50. | monomer | 100.0 | 1×L9S; 1×EDO; | |||
| Structure of BTK with RN486 | monomer | 100 | 1×7G6; | |||
| Co-structure of BTK kinase domain with L-005191930 inhibitor | monomer | 100 | 1×ULY; 1×5WE; | |||
| BTK1 SOAKED WITH COMPOUND 24 | monomer | 100 | 1×X9S; 5×DMS; | |||
| Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-ca… | monomer | 98.49 | 1×2V1; | |||
| Bruton's tyrosine kinase in complex with compound 65 | monomer | 100.0 | 1×0B0; | |||
| Bruton's tyrosine kinase in complex with an orthosteric inhibitor | monomer | 100.0 | 1×DMS; 1×Y8C; | |||
| Crystal structure of the human BTK kinase domain | monomer | 100.0 | ||||
| Bruton's tyrosine kinase (BTK) with pyridazinone compound 23 | monomer | 100 | 2×SO4; 2×GOL; 1×PG0; 1×3YO; | |||
| Bruton's tyrosine kinase (BTK) with pyridazinone compound 9 | monomer | 100 | 2×SO4; 2×GOL; 1×PG0; 1×6XL; | |||
| Co-crystal structure of BTK kinase domain with inhibitor | monomer | 100 | 1×IS4; 1×EDO; | |||
| Crystal structure of BTK kinase domain in complex with pirtobrutinib | monomer | 100 | 1×Y7W; 1×SO4; 2×GOL; 1×BTB; | |||
| Bruton's tyrosine kinase (BTK) with compound G-744 | monomer | 100 | 2×SO4; 2×GOL; 2×PG0; 1×9B1; | |||
| BTK kinase domain with inhibitor 1 | monomer | 100.0 | 1×5WF; 1×5WE; 1×CL; | |||
| BTK1 COCRYSTALLIZED WITH RN983 | monomer | 100 | 1×7G7; | |||
| CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m… | monomer | 98.48 | 1×GMQ; | |||
| Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymethy… | monomer | 98.48 | 1×3OV; 2×DMS; | |||
| BTK complex with compound 13 | monomer | 100 | 3×SO4; 1×DY4; 1×GOL; | |||
| Crystal structure of BTK C481S kinase domain in complex with pirtobrutinib | monomer | 99.62 | 1×Y7W; 1×SO4; 2×GOL; 1×BTB; | |||
| CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-… | monomer | 98.48 | 1×GMW; | |||
| Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-fl… | monomer | 100.0 | 1×73T; | |||
| Crystal structure of BTK kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl)-… | monomer | 98.48 | 1×2V2; 2×DMS; | |||
| Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazine-… | monomer | 98.48 | 1×481; 2×DMS; | |||
| BTK Fluorocyclopropyl amide inhibitor, Compound 25 | monomer | 100 | 1×V1G; 2×SO4; | |||
| CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815 | monomer | 100 | 2×SO4; 1×BXM; | |||
| CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625 | monomer | 99.62 | 1×GOL; 2×SO4; 1×BXJ; | |||
| Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m… | monomer | 98.48 | 1×3OU; 2×DMS; | |||
| BTK complex with compound 7 | monomer | 100 | 3×SO4; 1×DTJ; 1×GOL; | |||
| Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin-1… | monomer | 98.48 | 1×2V3; 2×DMS; | |||
| BTK complex with compound 10 | monomer | 100 | 3×SO4; 1×DVJ; | |||
| Crystal structure of bruton's tyrosine kinase mutant V555R in complex with dasatinib | monomer | 100.0 | 1×1N1; | |||
| Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiperaz… | monomer | 98.48 | 1×BNB; | |||
| Bruton's tyrosine kinase in complex with covalent inhibitor compound 27 | monomer | 100.0 | 1×V7I; | |||
| Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-… | monomer | 98.48 | 1×3P0; | |||
| BTK complex with compound 11 | monomer | 100 | 4×SO4; 1×DVD; | |||
| Crystal structure of bruton's tyrosine kinase in complex with inhibitor CGI1746 | monomer | 100 | 3×SO4; 1×BME; 1×746; | |||
| BTK in complex with an inhibitor | monomer | 100 | 1×L0Z; | |||
| Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834 | monomer | 100 | 3×SO4; 1×2VL; | |||
| Crystal structure of Bruton agammaglobulinemia tyrosine kinase complexed with BMS-809959 aka 4-tert… | monomer | 100.0 | 1×2P5; | |||
| Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R… | monomer | 100 | 1×4UQ; | |||
| Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2e | monomer | 100 | 1×9M3; | |||
| The PH domain of Bruton's tyrosine kinase mutant R28C | monomer | 99.39 | 1×MG; 1×ZN; | |||
| Crystal Structure of 1-methylindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros… | monomer | 99.39 | 1×MG; 3×72V; 1×ZN; | |||
| Crystal Structure of 5-chloroindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros… | monomer | 99.36 | 1×3IS; 1×ZN; 1×MG; | |||
| Crystal Structure of 5-(trifluoromethoxy)indoline-2,3-dione covalently bound to the PH domain of Br… | monomer | 100.0 | 1×Q1B; 1×MG; 1×ZN; | |||
| Crystal Structure of 1,5-dimethylindoline-2,3-dione covalently bound to the PH domain of Bruton's t… | monomer | 99.39 | 1×ZN; 1×MG; | |||
| PH domain of Bruton's tyrosine kinase bound to compound 1 | monomer | 99.36 | 2×NXT; 1×MG; 1×ZN; | |||
| Crystal Structure of 5-bromoindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosi… | monomer | 99.38 | 1×NYQ; 1×ZN; 1×MG; | |||
| Crystal structure of PH domain of Bruton's tyrosine kinase | monomer | 100.0 | 1×ZN; 1×4PT; | |||
| Solution Structures of the SH2 domain of Bruton's Tyrosine Kinase | monomer | 100 | ||||
| SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, 42 STRUCTURES | monomer | 98.46 | ||||
| SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, MINIMIZED AVERAGE STRUCTURE | monomer | 98.46 | ||||
| NMR Study of the SH3 Domain From Bruton's Tyrosine Kinase, 20 Structures | monomer | 100 | ||||
7 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8gmb.1.A | monomer | 0.74 | 95.90 | |||
| 1qcf.1.A | monomer | 0.71 | 38.66 | |||
| 1y57.1.A | monomer | 0.69 | 38.62 | |||
| 1opl.2.A | monomer | 0.69 | 39.82 | |||
| 1k9a.1.A | monomer | 0.68 | 37.30 | |||
| 4y93.1.A | monomer | 0.61 | 1×ZN; | 95.96 | ||
| 8s93.1.A | monomer | 0.59 | 1×ZN; | 92.34 | ||